Julie McHugh joins ViroPharma board
This article was originally published in Scrip
Executive Summary
Rare-disease focused biopharmaceutical company ViroPharma has appointed Julie McHugh to its board of directors. Ms McHugh is currently chief operating officer of Endo Pharmaceuticals, and was previously CEO of Nora Therapeutics. She is also on the board of directors of the Biotechnology Industry Organization (BIO), the New England Health Institute and the Nathaniel Adamaczyk Foundation.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.